Jazz Pharmaceuticals JAZZ Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent
Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent at other companies
Other financials
Where this comes from
Reported directly by Jazz Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance.
The official record: Jazz Pharmaceuticals’s 10-K, filed February 24, 2026, on SEC EDGAR. View the filing →
Ask your AI about Jazz Pharmaceuticals's effective income tax rate reconciliation, change in deferred tax assets valuation allowance, percent.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Jazz Pharmaceuticals's effective income tax rate reconciliation, change in deferred tax assets valuation allowance, percent?
- Jazz Pharmaceuticals (JAZZ) reported effective income tax rate reconciliation, change in deferred tax assets valuation allowance, percent of 31.8% in Q4 2025.
- What does effective income tax rate reconciliation, change in deferred tax assets valuation allowance, percent mean?
- The percentage impact on the effective tax rate caused by changes in deferred tax asset valuation reserves.
- How do you interpret effective income tax rate reconciliation, change in deferred tax assets valuation allowance, percent?
- A negative impact reduces the effective tax rate, while a positive impact increases it, reflecting changes in tax asset realization expectations.
- How does effective income tax rate reconciliation, change in deferred tax assets valuation allowance, percent compare across companies?
- Standard component of effective tax rate reconciliations across all industries.